Drug Use-Results Survey of Betanis Tablets in Japan

• Status: Completed
• Trial end date: 2014-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is to determine the following information.

1. The occurrence of adverse drug reactions in clinical settings.

2. Factors potentially impacting safety, effectiveness, and other aspects.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Treatments: Mirabegron

Criteria

Inclusion Criteria:

• Patients who received mirabegron for the first time for the treatment of urinary urgency, daytime frequency, and urgency incontinence associated with overactive bladder.